Matthew Moll, MD, is a current Alpha-1 Foundation In-Cycle Grants Program grantee. Through A1F’s Grants Award Program, Dr. Moll’s research focuses on leveraging genetics and other “omics” approaches to enable early identification and therapeutic interventions for Alpha-1 Antitrypsin Deficiency, advancing efforts to improve outcomes and move closer to a cure.
Most recently, he presented at the 29th Gordon L. Snider Critical Issues Workshop, where his talk, “Applying Omics Resources to Predict AATD Disease Outcomes,” highlighted how these technologies can help predict disease progression and identify new therapeutic targets.
